LifeSemantics Valuation
Is A347700 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of A347700 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate A347700's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate A347700's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A347700?
Key metric: As A347700 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is A347700's PS Ratio? | |
|---|---|
| PS Ratio | 8.3x |
| Sales | ₩7.15b |
| Market Cap | ₩59.11b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 8.6x |
| Enterprise Value/EBITDA | -6.3x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does A347700's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 11.3x | ||
A032850 BIT Computer | 2.2x | n/a | ₩78.7b |
A263700 CarelabsLtd | 0.6x | n/a | ₩47.1b |
A311690 CJ Bioscience | 21.1x | n/a | ₩103.6b |
A384470 Coreline Soft | 21.3x | n/a | ₩94.2b |
A347700 LifeSemantics | 8.3x | n/a | ₩59.1b |
Price-To-Sales vs Peers: A347700 is good value based on its Price-To-Sales Ratio (8.3x) compared to the peer average (11.3x).
Price to Sales Ratio vs Industry
How does A347700's PS Ratio compare vs other companies in the Asian Healthcare Services Industry?
| 4 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 4 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: A347700 is expensive based on its Price-To-Sales Ratio (8.3x) compared to the Asian Healthcare Services industry average (4.7x).
Price to Sales Ratio vs Fair Ratio
What is A347700's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 8.3x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate A347700's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Access Bio
₩189.3b
Engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide.
A950130
₩5,600.00
7D
0.2%
1Y
-38.9%
Wonbiogen
₩44.8b
Develops and sells medical equipment in South Korea.
A307280
₩1,262.00
7D
1.9%
1Y
-18.7%
Boditech Med
₩356.7b
Offers instruments and diagnostic reagents in South Korea and internationally.
A206640
₩16,230.00
7D
1.3%
1Y
-5.0%